Business Wire

Firefly Bio Debuts With $94 Million Series A Financing

-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company --SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Firefly Bio emerg


Antibe Reports Q3 2024 Interim Financial and Operating Results

- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive design - Ended quarter with $25 million in cash and equivalents